Blanket Purchase Agreement V797D30226-VA797P13A0009

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to GC Biopharma USA, Inc. The contract has a ceiling value of $11,920,000.00 and a period of performance through August 5, 2025. The BPA is for the procurement of ALYGLO products and related services. No set-aside was used for this single-award contract. As a BPA, the agreement establishes pre-negotiated terms, conditions, and pricing for the agency to issue task orders against as...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Mayne Pharma Commercial LLC, doing business as Metrics Inc. The BPA is for the procurement of halobetasol and tazaroten pharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The single-award BPA has a ceiling value of $5,216,518.00 and a period of performance through May 28, 2025. As a foreign-owned, for-profit manufacturer of goods, Mayne...

This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian federal agency, to Merz Pharmaceuticals, LLC, a for-profit foreign-owned organization. The BPA is established under the GSA Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, with a ceiling value of $12,057,300.00 and a period of performance running through March 12, 2026. The purpose of this BPA is to provide the agency with the pharmaceutical products Ampyra and Inbrijia. No...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to PTC Therapeutics, Inc. as the prime contractor. The BPA, valued at a ceiling of $12,500.00, is for the procurement of EMFLAZA, a medication. The BPA was awarded on March 9, 2024, with a period of performance ending on March 14, 2026. The contract was a single award, with no set-aside used. As a BPA, this contract provides a streamlined mechanism for the agency to order and...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026. The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...

This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Fera Pharmaceuticals, LLC, a woman-owned small business. The BPA, valued at up to $255,000, is for the procurement of Phospholine Iodide, a pharmaceutical drug. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows the VA and other agencies to efficiently and compliantly acquire the needed pharmaceutical product from Fera...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs, to Astellas Pharma US, Inc., a foreign-owned for-profit pharmaceutical manufacturer. The BPA has a ceiling value of $296,500.00 and a period of performance through October 6, 2025. The purpose of this BPA is to facilitate the procurement of the oncology drugs XTANDI and XOSPATA by the VA and potentially other federal agencies. This BPA was established...

The Department of Veterans Affairs National Acquisition Center has awarded a Blanket Purchase Agreement (BPA) to Alexion Pharmaceuticals Inc. (doing business as Alexion) under the Pharmaceuticals and Drugs GSA Schedule. The single-award BPA has a potential value of $4,239,517.80 and a period of performance from September 1, 2022 through August 31, 2025. The purpose of this BPA is to allow VA medical centers and clinics nationwide to place orders for the drug Strensiq to treat patients with...